# Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve

Study · id `cardio:ct-nct02679261` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02679261](<https://clinicaltrials.gov/study/NCT02679261>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02679261

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

## Technical summary

Registry record NCT02679261. Randomized; quadruple masking; primary purpose treatment. Start 2016-06 (actual); primary completion 2021-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 220 participants (enrolled count; ClinicalTrials.gov record NCT02679261, source copy `cardio:ctgov-nct02679261-2021-02-18`, retrieved 2026-10-26)
- Started: 2016-06 (actual) (ClinicalTrials.gov record NCT02679261, source copy `cardio:ctgov-nct02679261-2021-02-18`, retrieved 2026-10-26)
- Primary completion: 2021-02 (actual) (ClinicalTrials.gov record NCT02679261, source copy `cardio:ctgov-nct02679261-2021-02-18`, retrieved 2026-10-26)
- Completion: 2021-02 (actual) (ClinicalTrials.gov record NCT02679261, source copy `cardio:ctgov-nct02679261-2021-02-18`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT02679261, source copy `cardio:ctgov-nct02679261-2021-02-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02679261-2021-02-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve
- Acronym: BICATOR
- Condition: Bicuspid Aortic Valve
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Placebo
- Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bicuspid aortic valve (`cardio:bicuspid-aortic-valve`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Hospital Universitari Vall d'Hebron Research Institute (`cardio:org-hospital-universitari-vall-d-hebron-research-institute`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial (`cardio:pubmed-38804148`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 77ede48e2c9058792f9582c2606c6236a74962e4fbd901f119779bd7aeb095e1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
